

Market Announcement

5 November 2020

Recce Pharmaceuticals Ltd (ASX: RCE) – Suspension from Official Quotation

Description

The securities of Recce Pharmaceuticals Ltd ('RCE') will be suspended from quotation immediately under Listing Rule 17.2, at the request of RCE, pending the release of an announcement relating to anti-viral testing results.

Issued by

Sandra Wutete

Senior Adviser, Listings Compliance (Perth)

5 November 2020

Sean Maloney
Adviser, Listings Compliance (Perth)
Level 40 Central Park
152 - 158 St George's Terrace
PERTH WA 6000

By email: tradinghaltsperth@asx.com.au

Dear Sean

Recce Pharmaceuticals Ltd (ASX:RCE) – Voluntary Suspension request


Pursuant to ASX Listing Rule 17.2, Recce Pharmaceuticals Ltd ACN 124 849 065 (**Company**) requests for its securities to be voluntarily suspended pending the release of an announcement relating to anti-viral testing results.

The Company requests that the voluntary suspension be effective immediately and remain in place until the earlier of the commencement of normal trading on Monday, 9 November 2020 or the release of an announcement by the Company in relation to the results.

The Company is not aware of any reason why the voluntary suspension should not be granted.

For any questions, please contact the undersigned on +61 2 8072 1400.

Yours faithfully



Alistair McKeough
Company Secretary



ASX: RCE

Head Office Level 36, 1 Macquarie Place, Gateway Tower, SYDNEY NSW 2000 **T** +61 (0)2 8075 4585 **F** +61 (0)2 8075 4584

R&D Centre - Perth Suite 10, 3 Brodie Hall Drive, Technology Park, BENTLEY WA 6102 **T** +61 (8) 9253 9800 **F** +61 (8) 9253 9899

Washington Office 1717 Pennsylvania Avenue NW, Suite 1025, WASHINGTON DC 20006 USA